Chimeric Therapeutics Overview
- Year Founded
-
2015
- Status
-
Public
- Employees
-
19
- Stock Symbol
-
CHM
Chimeric Therapeutics General Information
Description
Chimeric Therapeutics Ltd is an Australian clinical-stage cell therapy company focused on developing and commercialising a range of cell therapies in oncology. The group's products under development include T Cell Derived Autologous Therapies and Natural Killer (NK) Cell Derived Allogenic Therapies. T Cell Derived Autologous therapy works by engineering the T cells with the exact coordinates to attack and kill cancer. NK Cell Derived Allogenic Therapies from healthy donors can be manufactured on a large scale and, once administered, kill cancer. Its pipeline products include CDH17, CLTX, and CORE NK. The group has one reportable segment, being the research, development, and commercialisation of health technologies.
Contact Information
Website
www.chimerictherapeutics.comCorporate Office
- 62 Lygon Street, Level 3
- Carlton, Victoria 3053
- Australia
Corporate Office
- 62 Lygon Street, Level 3
- Carlton, Victoria 3053
- Australia
Chimeric Therapeutics Timeline
Chimeric Therapeutics Stock Performance
As of 30-Sep-2026, Chimeric Therapeutics’s current market cap is $248K with 118M shares.
(As of Wednesday Closing)
| Stock Price | Previous Close | 52 wk Range | Market Cap | Shares | Average Volume | EPS |
|---|---|---|---|---|---|---|
| $248K | 118M | 1.6M |
Chimeric Therapeutics Financials Summary
As of 30-Sep-2026, Chimeric Therapeutics has a trailing 12-month revenue of null.
|
In Thousands, USD |
TTM 30-Sep-2026 | FY 2026 30-Jun-2026 | FY 2025 30-Jun-2025 | FY 2024 30-Jun-2024 |
|---|---|---|---|---|
| EV | 164 | 725 | 1,955 | 9,130 |
| Revenue | 2,568 | |||
| EBITDA | (5,904) | (7,408) | ||
| Net Income | (6,749) | (8,211) | ||
| Total Assets | 14,090 | 10,209 | ||
| Total Debt | 0 | 2,403 |
Chimeric Therapeutics Valuation & Funding
| Deal Type | Date | Amount | Valuation/ EBITDA |
Post-Val | Status | Debt |
|---|
Chimeric Therapeutics Comparisons
Industry
Financing
Details
Chimeric Therapeutics Competitors (47)
One of Chimeric Therapeutics’s 47 competitors is Mustang Bio, a Formerly VC-backed company based in Waltham, MA.
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| Mustang Bio | Formerly VC-backed | Waltham, MA | ||||
| Allogene Therapeutics | Formerly VC-backed | South San Francisco, CA | ||||
| Denali Therapeutics | Formerly VC-backed | South San Francisco, CA | ||||
| Arovella Therapeutics | Corporation | Preston, Australia | ||||
| Fate Therapeutics | Formerly VC-backed | San Diego, CA |
Chimeric Therapeutics Signals
Chimeric Therapeutics Investors
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds | Contact Info |
|---|
Chimeric Therapeutics ESG
Peers Analysis
Peer performance insights compare the company’s ESG performance to the performance of selected peers to help inform future ESG decisions and drive internal performance improvements.
Global
Covered Companies
Rank
Percentile
Pharmaceuticals
Industry
Rank
Percentile
Biotechnology
Subindustry
Rank
Percentile
Chimeric Therapeutics FAQs
-
When was Chimeric Therapeutics founded?
Chimeric Therapeutics was founded in 2015.
-
Where is Chimeric Therapeutics headquartered?
Chimeric Therapeutics is headquartered in Carlton, Australia.
-
What is the size of Chimeric Therapeutics?
Chimeric Therapeutics has 19 total employees.
-
What industry is Chimeric Therapeutics in?
Chimeric Therapeutics’s primary industry is Drug Discovery.
-
Is Chimeric Therapeutics a private or public company?
Chimeric Therapeutics is a Public company.
-
What is Chimeric Therapeutics’s stock symbol?
The ticker symbol for Chimeric Therapeutics is CHM.
-
What is the current market cap of Chimeric Therapeutics?
The current market capitalization of Chimeric Therapeutics is $248K.
-
Who are Chimeric Therapeutics’s competitors?
Mustang Bio, Allogene Therapeutics, Denali Therapeutics, Arovella Therapeutics, and Fate Therapeutics are some of the 47 competitors of Chimeric Therapeutics.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process